awmsg logo



deferasirox (Exjade®)


Reference No. 105

Publication date:
18/07/2008


Appraisal information

deferasirox (Exjade®) dispersible tablet


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Nutrition and blood
NMG meeting date: 14/05/2008
AWMSG meeting date: 13/06/2008
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0808
Ministerial ratification: 17/07/2008

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Deferasirox (Exjade®) is recommended for use within NHS Wales for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older. It is also recommended for the treatment of chronic iron overload due to blood transfusions when desferrioxamine (DFO) therapy is contraindicated or inadequate in the following patient groups: - in patients with other anaemias, - in patients aged 2 to 5 years, - in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (< 7 ml/kg/month of packed red blood cells). Deferasirox (Exjade®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download